The role of anti-inflammatory treatment in psychiatric disorders

Psychiatria Danubina

Volumn 25, Issue 3, 2013, Pages 292-298

  Müller, Norbert ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

COX 2 inhibition; Inflammation; Major depression; Schizophrenia; Treatment

Indexed keywords

AMISULPRIDE; CELECOXIB; CIMICOXIB; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; FLUOXETINE; GLUTAMIC ACID; ICOSAPENTAENOIC ACID; KYNURENINE; PROSTAGLANDIN E2; REBOXETINE; RISPERIDONE; ROFECOXIB; SERTRALINE; TRYPTOPHAN;

AMINO ACID METABOLISM; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MENTAL DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSIVE DISORDER, MAJOR; HUMANS; SCHIZOPHRENIA;

EID: 84885193191     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S: Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord 2012; 141:308-314.
2. Ahuja N, Carroll BT: Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol Biol Psychiatry 2007; 31:968-969.
3. Akhondzadeh S, Jafari S, Raisi F, Ghoreishi A: A clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Booklet WPA Section on Immunology and Psychiatry Workshop PsychoNeuroImmunology 2008.
4. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26:607-611.
5. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B: Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90:179-185.
6. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, MacKinnon A, McGorry PD, Berger GE: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebocontrolled trial. Arch Gen Psychiatry 2010; 67:146-154.
7. Begemann M, Sargin D, Rossner MJ, Bartels C, Theis F, Wichert SP, Stender N, Fischer B, Sperling S, Stawicki S, Wiedl A, Falkai P, Nave KA, Ehrenreich H: Episodespecific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med 2008; 14:546-552.
8. Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM: Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36:857-870.
9. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168:1303-1310.
10. Bentsen H: The Norwegian study on the treatment of schizophrenia and schizoaffective disorder with ethyl-EPA and antioxidants. Presented at second conference on Brain Phospholipids, Aviemore, Scotland, March, 2006.
11. Berger GE: Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: A double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients. Int. J. Neuropsychopharmacol 2004; 8:S422.
12. Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascedda F, Kriwin P, Mendlewicz J: Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006; 21:219-225.
13. Casolini P, Catalani A, Zuena AR, Angelucci L: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002; 68:337-343.
14. Chaves C, Marque CR, Chaudhry IB, Hussain FM, Oliveira JP, Wichert-Ana L: Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia (abstract). Schizophr Bull 2009; 35:354.
15. Collantes-Esteves E, Fernandez-Perrez Ch: Improved selfcontrol of ostheoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in spain. Curr Med Res Opin 2003; 19:402-410.
16. Cumiskey D, Curran BP, Herron CE, O'Connor JJ: A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology 2007; 52:1616-1623.
17. Dantzer R, Bluthe RM, Castanon N, Kelly KW, Konsman JP, Laye S, Lestage J, Parnet P: Cytokines, sickness behaviior, and depression. In: Ader, R. (Ed.), Psychoneuroimmunology Elsevier, New York, 2007; pp. 281-318.
18. Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Yolken RH: Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003; 160:2234-2236.
19. Dickerson FB, Stallings CR, Boronow JJ, Origoni AE, Sullens A, Yolken RH: Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. Schizophr Res 2009a; 107:147-149.
20. Dickerson FB, Stallings CR, Boronow JJ, Origoni AE, Yolken RH: A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr Res 2009b; 112:198-199.
21. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle- Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmacher T, Maier W, Siren AL, Klosterkotter J, Falkai P, Ruther E, Aldenhoff JB, Krampe H: Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007; 12:206-220.
22. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ: Randomized, placebo-controlled study of ethyleicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159:1596-1598.
23. Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, van Rensburg SJ, Maritz JS, Murck H: The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 2006; 84:112-120.
24. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158:2071-2074.
25. Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, Riedel M, Muller N: The association of infectious agents and schizophrenia. World J Biol Psychiatry 2010; 11:739-743.
26. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch- Verbin H, Gal G, Fennig S, Treves I, Kron S: A doubleblind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71:138-149.
27. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She JX, Hofig A, Dennis MA, Fuller K, Cook R, Schatz D, Moldawer LL, Clare-Salzler MJ: Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 1999; 104:515-523.
28. Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, Kaufmann WE, Vehmas A, Andreasson KI: Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006; 141:1149-1162.
29. Meyer U, Schwarz MJ, Müller N: Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011; 132:96-110.
30. Mizoguchi H, Takuma K, Fukakusa A, Ito Y, Nakatani A, Ibi D, Kim HC, Yamada K: Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) 2008; 196:233-241.
31. Müller N, Krause D, Dehning S, Musil R, Schennach- Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M: Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010a; 121:119-124.
32. Müller N, Myint AM, Schwarz MJ: The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin Neurosci 2009; 11:319-332.
33. Müller N, Myint AM, Schwarz MJ: Inflammation in schizophrenia. Am J Psychiatry 2012a; (in press).
34. Müller N, Riedel M, Dehning S, Spellmann I, Müller- Arends A, Cerovecki A, et al: Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology 2004a; 29:176.
35. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159:1029-1034.
36. Müller N, Riedel M, Schwarz MJ, Engel RR: Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005a; 255:149-151.
37. Müller N, Schwarz MJ: Immune System and Schizophrenia. Curr Immunol Rev 2010b; 6:213-220.
38. Müller N, Schwarz MJ: Immunological Treatment Options for Schizophrenia. Curr Pharm Biotechnol 2012b; 13:1606-1613.
39. Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 2006; 11:680-684.
40. Müller N, Schwarz MJ, Riedel M: COX-2 inhibition in schizophrenia: focus on clinical effects of celecoxib therapy and the role of TNF-alpha. In Eaton WW (ed): Medical and psychiatric comorbidity over the course of life, 265-276. American Psychiatric Publishing, 2005b.
41. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M: COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 2004b; 254:14-22.
42. Müller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M, Dehning S, Gruber R, Schwarz MJ: Impaired monocyte activation in schizophrenia. Psychiatry Res 2012c; 198:341-346.
43. Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE: Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007; 14:65-71.
44. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta- Soares GB, Frey BN, Bowden CL, Soares JC: Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23:87-94.
45. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU: Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Metaanalytic Investigation of Randomized Controlled Trials. Schizophr Bull 2013; May 29 [Epub ahead of print].
46. Peet M: Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 2008; 45:19-25.
47. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK: Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49:243-251.
48. Peet M, Horrobin DF: A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr Res 2002; 36:7-18.
49. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH: A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression: The Role of Baseline Inflammatory Biomarkers. Arch Gen Psychiatry 2012; 1-11.
50. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D: Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57:1594-1596.
51. Rappart F, Müller N: Celecoxib Add-on Therapy does not have beneficial antipsychotic Effects over Risperidone alone in Schizophrenia. Neuropsychopharmacology 2004; 29(Suppl 1):222.
52. Ross BM, Seguin J, Sieswerda LE: Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007; 6:21.
53. Saavedra JM, Sanchez-Lemus E, Benicky J: Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology 2011; 36:1-18.
54. Sandrini M, Vitale G, Pini LA: Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm Res 2002; 51:154-159.
55. Schwieler L, Erhardt S, Erhardt C, Engberg G: Prostaglandin- mediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 2005; 112:863-872.
56. Sommer IE, de WL, Begemann M, Kahn RS: Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012; 73:414-419.
57. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebocontrolled randomised phase III trial. Lancet 2006; 367:29-35.
58. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS: Microglia activation in recent-onset schizophrenia: a quantitative (R)- [11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64:820-822.
59. Wagner von Jauregg J: Fieberbehandlung bei Psychosen. Wien Med Wochenschr 1926; 76:79-82.
60. Weschenfelder J, Sander C, Kluge M, Kirkby KC, Himmerich H: The influence of cytokines on wakefulness regulation: clinical relevance, mechanisms and methodological problems. Psychiatr Danub 2012; 24:112-126.
61. Wüstenberg T, Begemann M, Bartels C, Gefeller O, Stawicki S, Hinze-Selch D, Mohr A, Falkai P, Aldenhoff JB, Knauth M, Nave KA, Ehrenreich H: Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry 2011; 16:26-36.
62. Zhang Y, Chun Chen D, Long Tan Y, Zhou DF: A doubleblind, placebo-controlled trial of celecoxib added to risperidone in first-episode and drug-naive patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256(Suppl 2):50.